C-MER Medical Holdings Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de C-MER Eye Care Holdings.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Healthcare	19.2%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	01 Sep 2023

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Not Many Are Piling Into C-MER Medical Holdings Limited (HKG:3309) Stock Yet As It Plummets 27%

Sep 04

Shareholders Will Probably Hold Off On Increasing C-MER Eye Care Holdings Limited's (HKG:3309) CEO Compensation For The Time Being

May 21

C-MER Eye Care Holdings' (HKG:3309) Earnings May Just Be The Starting Point

Apr 29

C-MER Eye Care Holdings Limited's (HKG:3309) 26% Share Price Plunge Could Signal Some Risk

Feb 02

C-MER Eye Care Holdings (HKG:3309) Might Be Having Difficulty Using Its Capital Effectively

Jan 17

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como C-MER Medical Holdings no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

SEHK:3309 - Estimaciones futuras de los analistas y datos financieros pasados (HKD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2024	2,309	114	185	281	1
6/30/2024	1,896	63	146	301	N/A
3/31/2024	1,910	63	196	331	N/A
12/31/2023	1,924	62	245	361	N/A
9/30/2023	1,862	28	204	311	N/A
6/30/2023	1,801	-7	162	261	N/A
3/31/2023	1,766	-14	118	213	N/A
12/31/2022	1,732	-22	74	165	N/A
9/30/2022	1,602	1	60	159	N/A
6/30/2022	1,473	23	45	154	N/A
3/31/2022	1,293	22	30	149	N/A
12/31/2021	1,113	22	15	144	N/A
9/30/2021	1,036	25	99	161	N/A
6/30/2021	959	28	184	178	N/A
3/31/2021	829	11	36	144	N/A
12/31/2020	700	-6	-111	110	N/A
9/30/2020	636	-10	-222	99	N/A
6/30/2020	573	-13	-334	88	N/A
3/31/2020	575	14	-184	112	N/A
12/31/2019	576	41	-35	137	N/A
9/30/2019	539	53	9	119	N/A
6/30/2019	502	64	53	102	N/A
3/31/2019	466	53	30	71	N/A
12/31/2018	429	43	7	41	N/A
9/30/2018	396	35	-7	41	N/A
6/30/2018	363	27	-21	41	N/A
3/31/2018	341	31	N/A	55	N/A
12/31/2017	311	40	N/A	65	N/A
9/30/2017	293	46	N/A	63	N/A
6/30/2017	274	52	N/A	60	N/A
3/31/2017	267	55	N/A	59	N/A
12/31/2016	249	47	N/A	53	N/A
12/31/2015	199	38	N/A	51	N/A
12/31/2014	156	22	N/A	43	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de 3309 es superior a la tasa de ahorro (2%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de 3309 crezcan más rápidamente que el mercado Hong Kong

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de 3309 crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de 3309 crezcan más rápidamente que el mercado de Hong Kong.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de 3309 crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de 3309 se prevé que sea elevada dentro de 3 años.

C-MER Medical Holdings Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 12% to HK$4.50

C-MER Eye Care Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

C-MER Eye Care Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2021

Recent updates

Chairman & CEO recently bought HK$776k worth of stock

Investor sentiment deteriorates as stock falls 18%

Not Many Are Piling Into C-MER Medical Holdings Limited (HKG:3309) Stock Yet As It Plummets 27%

First half 2024 earnings released: EPS: HK$0.025 (vs HK$0.024 in 1H 2023)

C-MER Medical Holdings Limited to Report First Half, 2024 Results on Aug 29, 2024

Chairman & CEO recently bought HK$841k worth of stock

Shareholders Will Probably Hold Off On Increasing C-MER Eye Care Holdings Limited's (HKG:3309) CEO Compensation For The Time Being

C-MER Eye Care Holdings' (HKG:3309) Earnings May Just Be The Starting Point

C-MER Eye Care Holdings Limited, Annual General Meeting, May 28, 2024

New major risk - Revenue and earnings growth

C-MER Eye Care Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

C-MER Eye Care Holdings Limited's (HKG:3309) 26% Share Price Plunge Could Signal Some Risk

C-MER Eye Care Holdings (HKG:3309) Might Be Having Difficulty Using Its Capital Effectively

Price target decreased by 12% to HK$4.50

First half 2023 earnings released: EPS: HK$0.024 (vs HK$0.012 in 1H 2022)

C-MER Eye Care Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

C-MER Eye Care Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

C-MER Eye Care Holdings Limited Announces Board Changes, Effective July 3, 2023

Insufficient new directors

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

A Look At The Intrinsic Value Of C-MER Eye Care Holdings Limited (HKG:3309)

Full year 2022 earnings released: HK$0.018 loss per share (vs HK$0.019 profit in FY 2021)

Now 22% undervalued

Capital Allocation Trends At C-MER Eye Care Holdings (HKG:3309) Aren't Ideal

Insufficient new directors

Chairman & CEO recently bought HK$1.9m worth of stock

Chairman & CEO recently bought HK$1.3m worth of stock

Insufficient new directors

Is C-MER Eye Care Holdings (HKG:3309) A Risky Investment?

First half 2022 earnings released: EPS: HK$0.012 (vs HK$0.012 in 1H 2021)

Insufficient new directors

C-MER Eye Care Holdings Limited to Report First Half, 2022 Results on Aug 30, 2022

C-MER Eye Care Holdings Limited, Annual General Meeting, May 24, 2022

Full year 2021 earnings released: EPS: HK$0.019 (vs HK$0.006 loss in FY 2020)

C-MER Eye Care Holdings Limited Recommends No Payment of Any Final Dividend for the Year Ended 31 December 2021

C-MER Eye Care Holdings Limited (SEHK:3309) entered into the Sale and Purchase agreements to acquire Champion Eye Centre Limited from Yeung, Hung, Pauline Chan, Ko, DN Chan,Yip, and the Estate of Cheung for HKD 56.02 million.

Executive Director exercised options to buy HK$1.7m worth of stock.

C-MER Eye Care Holdings Limited (SEHK:3309) entered into an Equity Transfer Agreement to acquire 7% stake in Shenzhen Aikangjian Group Co., Ltd. from Shenzhen Capital Group Co., Ltd. for CNY 45.5 million

First half 2021 earnings released: EPS HK$0.012 (vs HK$0.02 loss in 1H 2020)

C-MER Eye Care Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2021

Independent Non-Executive Director recently bought HK$1.6m worth of stock

C-MER Eye Care Holdings Limited Approves Final Dividend for the Year Ended 31 December 2020

Upcoming dividend of HK$0.02 per share

Full year 2020 earnings released: HK$0.006 loss per share (vs HK$0.04 profit in FY 2019)

Full year 2020 earnings released: HK$0.006 loss per share (vs HK$0.04 profit in FY 2019)

C-MER Eye Care Holdings Limited to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day high: HK$6.89

C-MER Eye Care Holdings Limited (SEHK:3309) signed a Purchase Agreement to acquire 60% stake in CAD/CAM Restorative Dental Centre Limited from YIU Bun Ka for HK$12.9 million.

New 90-day high: HK$6.44

Update: C-MER Eye Care Holdings (HKG:3309) Stock Gained 25% In The Last Year

Independent Non-Executive Director recently bought HK$1.8m worth of stock

C-MER Eye Care Holdings Limited Announces Board Changes

New 90-day low: HK$5.58

Independent Non-Executive Director recently bought HK$208k worth of stock

New 90-day low: HK$5.86

First half earnings released

Independent Non-Executive Director recently bought HK$138k worth of stock

Independent Non-Executive Director recently bought HK$130k worth of stock

First half earnings released

C-MER Eye Care Holdings Limited to Report First Half, 2020 Results on Aug 28, 2020

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento